BBIO

NASDAQ 已收盘

BridgeBio Pharma

78.18 USD
▲+0.17+0.22%
盘后 78.90 +0.92%
2026-11-19
市值
$15.07B
市盈率
—
EPS
-3.04
股息率
—
52 周区间
62.50 – 93.42
成交量
2.17M
Beta
0.94
目标价
107.00
52W 低 62.5052W 高 93.42
价格走势

公司简介

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ...

关联新闻